Berenberg Bank Reaffirms Their Hold Rating on Bayer (BAYRY)
Berenberg Bank analyst maintained a Hold rating on Bayer yesterday and set a price target of $12.35.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In addition to Berenberg Bank, Bayer also received a Hold from TipRanks – Google’s Google Drug Manufacturers – General in a report issued today. However, on January 6, Barclays upgraded Bayer (Other OTC: BAYRY) to a Buy.
Based on Bayer’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $11.29 billion and a GAAP net loss of $1.13 billion. In comparison, last year the company earned a revenue of $9.97 billion and had a GAAP net loss of $4.18 billion
Read More on BAYRY:
Disclaimer & DisclosureReport an Issue
- Bayer Stock Soars as U.S. Supreme Court Agrees to Review Roundup Appeal
- Bayer ‘welcomes’ Supreme Court review of Durnell litigation
- U.S. Supreme Court to hear Bayer’s appeal of Roundup lawsuits, Bloomberg says
- Bayer to acquire AT-01 and AT-05 from Attralus, terms undisclosed
- Bayer’s New Phase 4 ATTR-CM Study Tests Switching From Tafamidis to Acoramidis
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.